|
|
|
| Nov. 5, 2009 |
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
|
| Nov. 4, 2009 |
Call for Applications: The Amgen Award for Science Teaching Excellence
|
| Oct. 30, 2009 |
Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints
|
| Oct. 21, 2009 |
Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent to $1.49
|
| Oct. 19, 2009 |
Amgen Provides Update on Status of Prolia(TM) (Denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA)
|
| Oct. 16, 2009 |
Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting
|
| Oct. 15, 2009 |
Amgen Announces Webcast of 2009 Third Quarter Financial Results
|
| Sep. 24, 2009 |
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
|
| Sep. 22, 2009 |
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
|
| Sep. 22, 2009 |
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
|
| Sep. 21, 2009 |
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
|
| Sep. 17, 2009 |
Amgen to Present at the UBS Global Life Sciences Conference
|
| Sep. 16, 2009 |
Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress
|
| Sep. 16, 2009 |
Amgen Scholars Europe Programme Convenes Undergraduates From 15 Countries for Innovative Science Research
|
| Sep. 15, 2009 |
Appeals Court Affirms Patent Infringement Rulings Against Roche's peg-EPO Product
|
| Sep. 14, 2009 |
Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
|
| Sep. 13, 2009 |
Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis
|
| Sep. 11, 2009 |
Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
|
| Sep. 10, 2009 |
Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
|
| Sep. 10, 2009 |
Edie Falco and Cynthia Nixon Appear in New Stand Up To Cancer(TM) PSAs Designed to Educate Cancer Patients About the Importance Of Lowering One's Risk of Infection During Treatment
|
| Sep. 9, 2009 |
Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope
|
| Sep. 8, 2009 |
Amgen to Present at the Thomas Weisel Healthcare Conference
|
| Sep. 4, 2009 |
Amgen to Present at the Baird Healthcare Conference
|
| Sep. 2, 2009 |
Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis
|
| Aug. 25, 2009 |
Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
|
| Aug. 17, 2009 |
Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer
|
| Aug. 13, 2009 |
Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
|
| Aug. 13, 2009 |
Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs
|
| Aug. 11, 2009 |
Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
|
| Aug. 6, 2009 |
Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
|
| Aug. 4, 2009 |
Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
|
| Aug. 3, 2009 |
Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
|
| Jul. 27, 2009 |
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
|
| Jul. 27, 2009 |
Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29
|
| Jul. 23, 2009 |
Amgen Announces Webcast of 2009 Second Quarter Financial Results
|
| Jul. 20, 2009 |
Amgen Scholars Discover Their Potential During Summer Science Research Program and National Symposium
|
| Jul. 17, 2009 |
Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab)
|
| Jul. 9, 2009 |
Amgen Appoints Rebecca M. Henderson to the Company's Board of Directors
|
| Jul. 7, 2009 |
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
|
| Jul. 6, 2009 |
Winners of the Addressing Psoriasis(TM) Contest Selected to Walk the Runway in New York City Fashion Show Hosted by Tim Gunn
|
| Jun. 22, 2009 |
Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
|
| Jun. 17, 2009 |
34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence
|
| Jun. 8, 2009 |
Amgen to Present at the Goldman Sachs Global Healthcare Conference
|
| Jun. 7, 2009 |
New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure in Patients With Chronic ITP
|
| May. 27, 2009 |
VIDEO from Medialink and Amgen: New Survey Highlights Growing Concern About Risk of Infection and Emerging Antibiotic Resistance in Cancer Patients
|
| May. 27, 2009 |
New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance
|
| May. 26, 2009 |
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
|
| May. 15, 2009 |
Amgen Highlights Data to Be Presented at ASCO
|
| May. 13, 2009 |
Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference
|
| May. 6, 2009 |
Amgen Announces Voting Results Of Annual Meeting Of Stockholders
|
| Apr. 30, 2009 |
Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
|
| Apr. 30, 2009 |
Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
|
| Apr. 23, 2009 |
Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
|
| Apr. 20, 2009 |
Amgen Announces Webcast of 2009 First Quarter Financial Results
|
| Apr. 16, 2009 |
Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR
|
| Mar. 30, 2009 |
Amgen to Present at the Citigroup Biotech Day
|
| Mar. 16, 2009 |
Amgen to Present at the Cowen and Company Annual Healthcare Conference
|
| Mar. 9, 2009 |
Amgen to Present at the Barclays Capital Global Healthcare Conference
|
| Mar. 4, 2009 |
"Project Runway's" Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate that Patients Shouldn't Let Psoriasis Impact Personal Style
|
| Feb. 18, 2009 |
FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab
|
| Feb. 11, 2009 |
Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
|
| Feb. 6, 2009 |
Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
|
| Jan. 26, 2009 |
Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
|
| Jan. 22, 2009 |
Amgen's Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
|
| Jan. 20, 2009 |
Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
|
| Jan. 7, 2009 |
Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
|
